Malignant pericardial mesothelioma

Summary

Malignant pericardial mesothelioma (MONDO:0003805) is a disease. A subtype of pericardium cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	malignant pericardial mesothelioma
Mondo ID	MONDO:0003805
Orphanet	685004
DOID	DOID:6201
NCIT	C7631
SNOMED CT	109383000
UMLS	C1335381
MedGen	233322
GARD	0023676
Anatomy (UBERON)	UBERON:0002407
Is cancer (heuristic)	no

Also known as: malignant mesothelioma (disease) of pericardium · malignant mesothelioma of pericardium · malignant mesothelioma of the pericardium · pericardial malignant mesothelioma · pericardial mesothelioma · pericardium malignant mesothelioma (disease) · pericardium mesothelioma

Data availability: 1 HPO phenotype.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › cardiovascular cancer › heart cancer › pericardium cancer › malignant pericardial mesothelioma

Related subtypes (1): epicardium cancer

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.